Continue reading “Synspira Therapeutics Adds Drucy Borowitz, MD, to Board of Directors”
Author: Kathryn Kilroy
Synspira Therapeutics Presents Data at 34rd Annual North American Cystic Fibrosis Conference on Effect of SNSP113 on Recalcitrant Methicillin Resistant Staphylococcus aureus (MRSA)
Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis
Synspira Therapeutics Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference
Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors
Synspira Therapeutics Presents Data at 42nd Annual European Cystic Fibrosis Society Conference on Effect of SNSP113 on nontuberculosis Mycobacteria and Burkholderia Pulmonary Infections
Synspira Therapeutics SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease
Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union
Synedgen showcased in the Top 10 Cystic Fibrosis Stories of 2018 by CF News Today
Studies led by Synedgen and Keck Graduate Institute show Ion-Sugar Interaction in Airway Mucus Has Implications for CF.This researchaddresses ion interactions in different kinds of cell surfaces and water-containing gels. Understanding how each type of ion affects the structure, electrical potential, and fluid behavior of the airway-surface layers in the lung has direct implications for designing drug targets that influence pulmonary behavior. Read on Cystic Fibrosis News Today
Life Science Leader features Synspira in its Companies to Watch
SNSP113 is a glycopolymer licensed to Synspira from Synedgen as one of the first therapeutic molecules that uses this research to target airway health. SNSP113 is set to soon enter a Phase 1b clinical trial for treating cystic fibrosis (CF). SNSP113 targets biofilms and restores normal mucus in the lungs of patients with cystic fibrosis. Other compounds in the pipeline target non-CF bronchiectasis, pulmonary infection, and chronic obstructive pulmonary disease (COPD) Read on Life Science Leader